| Identification | |
| Name: | Benzenesulfonamide,4-(5-methyl-3-phenyl-4-isoxazolyl)- |
| Synonyms: | 4-(5-Methyl-3-phenylisoxazol-4-yl)benzenesulfonamide;4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide;benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-;Bextra(Valdecoxib);p-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide;4-(5-Methyl-3-phenylisoxazol-4-yl)benzenesulfonamide;4-(5-Methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide;Bextra; |
| CAS: | 181695-72-7 |
| Molecular Formula: | C16H14N2O3S |
| Molecular Weight: | 314.36 |
| InChI: | InChI=1/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20) |
| Molecular Structure: |  |
| Properties | |
| Density: | 1.303 g/cm3 |
| Refractive index: | 1.608 |
| Solubility: | Soluble in methanol and ethanol; freely soluble in organic solvents and alkaline (pH=12) aqueous solution Relatively insoluble in water (10 ug/mL) at 25 deg C and pH 7 |
| Appearance: | White Crystalline Powder |
| Color: | White crystalline powder |
| Usage: | A nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic properties in animal models. An inhibitor of prostaglandin synthesis primarily through inhibition of COX-2 |
| Safety Data | |
 |
|
